-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $47 Price Target

Benzinga·03/19/2025 12:41:56
Listen to the news
HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $47 price target.